Research Update: Israel (State of) Nov 03

  • ID: 2045339
  • November 2003
  • Region: Israel
  • Standard & Poors
1 of 3

On Nov. 24, 2003, Standard & Poor's Ratings Services affirmed its 'A-/A-1' foreign currency ratings, and 'A+/A-1' local currency ratings on the State of Israel. The outlook is negative. The ratings on Israel are supported by: An advanced, prosperous, and export-oriented economy. At $16,182, per capita income exceeds that in some EU countries and many of Israel's peers. Although growth has remained below potential over the past three years, a global recovery will lift the economy out of recession over the medium term. Renewed commitment to structural reforms. Despite vociferous resistance from vested interest groups, the government is expected to implement a downsizing of the public sector, as well as continuing with privatizations, and further liberalization of product and factor...

Companies mentioned in this report are:
- Israel (State of)

Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Product Type: Research Update
Research updates complement media releases. They offer more depth and detail than summary analyses by incorporating all information published in the media release. They are more up to date than summaries in that they are published simultaneously with media releases.

Note: Product cover images may vary from those shown
2 of 3

- Israel (State of)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.